18956075901
當前位置：上海富雨生物科技有限公司>>細胞庫 / 細胞培養>>普通細胞>> H-4-II-E大鼠肝細胞瘤（
大鼠肝細胞瘤H-4-II-E
| 種屬 | 大鼠 |
| 別稱 | H-4-II-E; H4IIE |
| 組織來源 | 肝臟 |
| 疾病 | 肝癌 |
| 傳代比例/細胞消化 | 1:2傳代,消化2-3分鐘 |
| 培養基配置 | MEM養基；10%胎牛血清；1%雙抗 |
| 簡介 | H-4- Ⅱ-E細胞可誘導產生芳香烴羥化酶 ，用于檢測環境樣品或食物提取物種皮克級的有機化合物。 |
| 形態 | 上皮細胞樣 |
| 生長特征 | 貼壁生長 |
| 倍增時間 | 每周 2 至 3 次 |
| 培養條件 | 氣相：空氣，95%；二氧化碳，5%。 溫度：37攝氏度，培養箱濕度為70%-80%。 |
| 凍存條件 | 凍存液 ：90%FBS ，DMSO 10%, 或使用非程序凍存液 ：貨號JY-H040 |
| 保藏機構 | ATCC; CRL-1548 |
| 產品使用 | 于科學研究 ，不可作為動物或人類疾病的治療產品使用。 |
Introduction: Blunt traumatic aortic injury (TAI) is a critical condition and a leading cause of mortality in trauma patients, often resulting from high-speed accidents. Thoracic endovascular aortic repair (TEVAR) has developed into the preferred therapeutic approach due to its minimally invasive nature and promising outcomes. This study evaluates the safety and efficacy of TEVAR for managing TAI over a 10-year period at a Level-1 trauma center.
Methods: A retrospective analysis was conducted on 19 patients with acute TAI treated with TEVAR between 2012 and 2022 at the University Hospital Zurich. Data were collected from digital records and analyzed according to the Fillinger TEVAR reporting framework. Outcomes included technical success, perioperative complications, and long-term graft durability.
請輸入賬號
請輸入密碼
請輸驗證碼
以上信息由企業自行提供，信息內容的真實性、準確性和合法性由相關企業負責，化工儀器網對此不承擔任何保證責任。
溫馨提示：為規避購買風險，建議您在購買產品前務必確認供應商資質及產品質量。
化工儀器網